Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05153772 · ClinicalTrials.gov registry record · Phase 2
Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients
A Phase 2 study of Neuroendocrine Tumors, sponsored by Orano Med.
- Active
- Registry status
- Phase 2
- Development phase
- 69
- Enrollment target
- 4
- Study locations
NCT05153772: Active Phase 2 study of Neuroendocrine Tumors, sponsored by Orano Med.
NCT05153772 is a Phase 2 study of Neuroendocrine Tumors that is active but no longer recruiting, run by Orano Med. The registered enrollment target is 69 participants, below the 178-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (61% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05153772, a Phase 2 study of Neuroendocrine Tumors, is active but no longer recruiting, sponsored by Orano Med.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 69 participants
- Enrollment target
- 4
- Study locations
Study Summary
Multicenter Phase 2 study of 212Pb-DOTAMTATE enrolling adult subjects with positive somatostatin positive neuroendocrine tumors with either no prior history of peptide receptor radionuclide therapy (PRRT naive) or prior history of peptide receptor radionuclide therapy (Previous PRRT)
Primary Outcome
The morphological imaging (CT/MRI) will be done before therapy and selected time points before therapy cycle to determine changes in the size of target lesions.
Conditions Studied
Interventions
- DRUG AlphaMedix
Study Locations (4)
Colorado
- Rocky Mountain Cancer Center - Denver
Florida
- Moffitt Cancer Center - Tampa
Louisiana
- Louisiana State University (LSU) Health Sciences Center - New Orleans - Metairie
Texas
- Excel Diagnostics and Nuclear Oncology Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2021-12-21 |
| Est. Completion | 2028-10 |
| Phase | Phase 2 |
What the registry record for NCT05153772 still lists
NCT05153772 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 69 participants, a relatively small participant target, below the 178-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (61% lower).
The record links to 1 condition, with Neuroendocrine Tumors appearing as the primary indexed condition, and to 1 intervention - of which AlphaMedix is the first listed.
NCT05153772 reports a single indexed study location in Colorado, Florida, Louisiana.
Frequently Asked Questions
What is clinical trial NCT05153772 about?
NCT05153772 is a clinical study titled "Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients". Multicenter Phase 2 study of 212Pb-DOTAMTATE enrolling adult subjects with positive somatostatin positive neuroendocrine tumors with either no prior history of peptide receptor radionuclide therapy (PRRT naive) or prior history of peptide receptor radionuclide therapy (Previous PRRT)
What is the current status of trial NCT05153772?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 69 participants. The study started on 2021-12-21. Estimated completion is 2028-10.
What conditions does trial NCT05153772 study?
This clinical trial studies the following conditions: Neuroendocrine Tumors.
What interventions are being tested in trial NCT05153772?
The interventions under investigation include: AlphaMedix (DRUG).
Who is sponsoring clinical trial NCT05153772?
This trial is sponsored by Orano Med, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05153772 being conducted?
This trial has 4 study locations across Colorado, Florida, Louisiana, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroendocrine Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05153772's enrollment target sits among peer trials
69 26th of 52 higher than 27 of 52 other Neuroendocrine Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neuroendocrine Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors
RECRUITING · Phase 2
-
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
RECRUITING · Phase 2
-
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04020575 · 69 participants · Phase 1
Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)
- NCT04163614 · 69 participants · NA
Blood Pressure Slopes and Ultrafiltration in Hemodialysis Patients
- NCT04164641 · 69 participants · NA
Noraxon myoRESEARCH™ Software Gait Analysis Evaluation and Orthotic Gait Correction in Reducing Diabetic Foot Ulceration Or Subsequent Amputation in Patients With a History of a Diabetic Foot Ulceration
- NCT04493372 · 69 participants · NA
Deciphering Preserved Autonomic Function After Spinal Cord Injury
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI